EAACI Congress 2025
BackOAS02 - Biologics in the combined airway
Friday 13 Jun, 13:15 PM -
14:45 PM Glasgow, United Kingdom
Carron 2
Oral Abstract Sessions
13:15
Efficacy of two years of treatment with anti-IL-5/R therapy for reduction in use of oral glucocorticoids in patients with eosinophilic granulomatosis with polyangiitis
13:27
Tezepelumab reduces OCS use and improves sino-nasal symptoms in OCS-dependent patients with severe asthma and comorbid chronic rhinosinusitis (overall and with nasal polyps): results from the phase 3b WAYFINDER study
13:39
Dupilumab Improves Lung Function and Reduces Exacerbation Frequency and IgE Levels in Patients with Asthma and Allergic Bronchopulmonary Aspergillosis (Phase 2 LIBERTY ABPA AIRED Study)
13:51
Impact of Immunogenicity on Clinical Outcomes in Patients from a Severe Asthma Unit Treated with Mepolizumab
14:03
Dupilumab Effectiveness Through Two Years in Patients with CRSwNP Treated in Real-World Practice: Results from the Global AROMA Registry
14:15
Improved Quality of Life, Early Symptom Control and Reduced Surgery with Mepolizumab in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Results from the SYNAPSE Study
14:27
REALITI-N: First Ambidirectional Cohort Study Evaluating Real-World Mepolizumab Use in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
